JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

REVIEW

    1. Research Institute of Internal and Preventive Medicine - Banch of the Institute of Cytology and Genetics RAN (Novosibirsk, Russian Federation)
    2. Novosibirsk Regional Oncology Center (Novosibirsk, Russian Federation)

    Abstract:The scientific review is devoted to the discussion of risk factors for colorectal cancer (CRC) morbidity and mortality which remains high and growing, especially in the civilized world. Factors are considered taking into account the degree of proof or the likelihood of their impact on morbidity and mortality. Risk factors related to the CRC proven include the geographical area and level of socio-economic development of the country of residence, race, hereditary a family history of bowel cancer, long current inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) associated with ulcerative colitis and Crohn’s disease and heavy smoking. Probable risk factors for CRC are physical inactivity, obesity (including in combination with diabetes mellitus type 2), high-dose consumption of alcohol, cholecystectomy, a history of frequent consumption of red meat and deficient in some nutrients (Ca, folate, selenium). As protective factors are discussed high physical activity and salicylates. Protective role of other factors against CRC requires additional research.

      1. Васильев С.В., Дудка В. В., Попов Д. Е. и соавт. Опыт применения скрининговых тестов в ранней диагностике колоректального рака. Вопросы онкологии, 2013, № 3, с. 555-556.
      2. Гусеинова З.К., Тайжанова Д. Ж., Таушева З. Б. и соавт. Частота распространенности и скрининг диагностика колоректального рака. Международный журнал прикладных и фундаментальных исследований, 2015, № 36, с. 190-197.
      3. Шаназаров Н. А., Машкин А. М., Батырбеков К. У., Мидленко А. А. Эпидемиологические аспекты колоректального рака на современном этапе. Современные проблемы науки и образования, 2014, № 3.
      4. DeBarros M., Causey M. W., Johnson E. K. et al. Outcome comparison following colorectal cancer surgery in an equal access system. Journal of surgical research, 2013, vol. 184, pp. 507-513.
      5. Опенко Т. Г., Решетников О. В., Курилович С. А., Светлова И. О., Белковец А. В. Колоректальный рак: тенденции за четверть века в Новосибирске, возможности раннего выявления и профилактика. Эксперимент и клин. Гастроэнтерология, 2014, № 6, с. 687-694.
      6. Neugent A. I. Cancer epidemiology and prevention. Sci Am. 2004, vol. 11, pp. 111-122.
      7. Dennis R., Tou S., Miller R. Colorectal cancer: prevention and early diagnosis. Medicine, 2011, vol. 39, № 5, pp. 243-249.
      8. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am. J. Clin. Nutr, 2007, vol. 86, № 3, pp. 836-842.
      9. Солодкий В. А. Ранняя диагностика колоректального рака. Врач, 2012, № 11, c. 20-23.
      10. Одинцова И. Н., Писарева Л. Ф., Хряпенков А. В. Эпидемиология злокачественных новообразований в мире. Сибирский онкологический журнал, 2015, № 5, c. 95-101.
      11. Lieberman D. A., Williams J. L., Holub J. L. et al. Race, ethnicity, and sex affect risk for polyps >9 mm in average-risk individuals. Gastroenterology, 2014, vol. 147, № 2, pp. 351-358.
      12. Obuch J.C., Ahnen D. J. Colorectal Cancer: Genetics is Changing Everything. GastroenterolClin North Am, 2016, vol. 45, № 3, pp. 459-476.
      13. Циммерман Я. С. Колоректальный рак: современное состояние проблемы. Российский журнал Гастроэнтерологии, Гепатологии, Колопроктологии, 2012, № 4, c. 5-16.
      14. Gelsomino F., Barbolini M., Spallanzani A. et al. The evolving role of microsatellite instability in colorectal cancer: A review. Cancer Treatment Reviews, 2016, vol. 51, pp. 19-26.
      15. Stoffel E.M., Yurgelun M. B. Genetic predisposition to colorectal cancer: Implications for treatment and prevention. Seminars in Oncology, 2016, vol. 43, № 5, pp. 536-542.
      16. National Comprehensive Cancer Network (NCCN) 19th Annual Conference. Presented March 13, 2014.
      17. Giardiello F. M., Trimbath J. D. Peutz-Jeghers syndrome and management recommendations. ClinGastroenterolHepatol, 2006, vol. 4, pp. 408-415.
      18. CancerResearch [Электронный ресурс]. - Режим доступа: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer#heading-Zero (дата обращения 10.11.2016)
      19. Shen Z., Yingjiang Y., Bin L. et al. Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis. The American Journal of Surgery, 2010, vol. 200, pp. 59-63.
      20. Колодей Е. Н. Язвенный колит и рак толстой кишки: актуальные и нерешенные вопросы диагностики. Медицинский альманах, 2013, № 1, c. 74-78.
      21. Holt P., Pendyala S. Obesity and Colorectal Cancer Risk. Gastroenterology, 2014, vol. 134, № 3, pp. 896.
      22. Lin J. H., Zhag S. M., Rexrode K. M. et al. Association Between Sex Hormones and Colorectal Cancer Risk in Men and Women. Clinical gastroenterology and hepatology, 2013, vol. 11, pp. 419-424.
      23. Anderson J. C. Smoking-associated Colorectal Cancer Risk: Do Micronutrients Help or Hurt?. Clinical gastroenterology and hepatology, 2013, vol. 11, pp. 416-418.
      24. Опенко Т. Г., Решетников О. В., Курилович С. A. и соавт. Колоректальный рак: тенденции за четверть века в Новосибирске, возможности раннего выявления и профилактика. Вопросы онкологии, 2014, N 6, с. 687-694.
      25. Murphy А., Strickler H. D., Stanczyk F. Z. et al. A Prospective Evaluation of Endogenous Sex Hormone Levels and Colorectal Cancer Risk in Postmenopausal Women. National cancer institute. URL: https://www.ncbi.nlm.nih.gov/pubmed/26232761# (дата обращения 14.10.2016)
      26. Chang L. C., Wu M. S., Tu C. H. et al. Metabolic syndrome and smoking may justify earlier colorectal cancer screening in men. Gastrointestinal endoscopy, 2014, vol. 79, № 6, pp. 961-969.
      27. Thomas T., Abrams K. A., Robinson R. J. et al. Cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment PharmacolTher, 2007, № 25, pp. 657-668.
      28. Brral M., Dohan A., Allez M. et al. Gastrointestinal cancers in inflammatory bowel disease: An update with emphasis on imaging findings. Critical reviews in oncology/hematology, 2016, vol. 97. pp. 30-46.
      29. Bhat S. K., East J. E. Colorectal cancer: prevention and early diagnosis. Colorectal cancer, 2015, vol. 43, № 6, pp. 295-298.
      30. Leufkens A. M., Siersema P. D., Boshuizen H. C. et al. Cigarette Smoking and Colorectal Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition Study. Clinical gastroenterology and hepatology, 2011, vol. 9, pp. 137-144.
      31. Станоевич У. С., Дехисси Е. И., Гребенкин Е. Н. и соавт. Патогенетические особенности колоректального рака на фоне нарушений жирового и углеводного. Вестник Российского научного центра рентгенорадиологии Минздрава России, 2013, № 13, c. 2-14.
      32. NationalCancerInstitute [Электронный ресурс]. - Режим доступа: https://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/physical-activity-fact-sheet (дата обращения 05.01.2017)
      33. Кручинина М. В., Курилович С. А., Громов А. А. и соавт. Метаболический синдром и риск развития колоректального рака. Атеросклероз, 2016, № 1, c. 46-60.
      34. Parkin D. M., Boyd L., Walker L. C. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Summary and conclusions. Br. J. Cancer, 2011, vol.105, pp. 77-81.
      35. Luo W., Cao Y., Liao C., Gao F. Diabetes mellitus and the incidence and mortality of colorectal cancer: A meta-analysis of twenty four cohort studies. Colorectal Disease, 2012, vol. 14, no. 11, pp. 1307-1312.
      36. Cho E, Smith-Warner SA, Ritz J, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann. Intern. Med, 2004, vol. 140, no. 8, pp. 603-13
      37. Baroudi O., Bammar-elgaaied A. Involvement of genetic factors and lifestyle on the occurrence of colorectal and gastric cancer. Critical reviews in oncology/hematology, 2016., vol. 107, pp. 72-37. 37.
      38. Fedirko V., Tramacere I., Bagnardi V. et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Annals of Oncology, 2011, vol. 22, no. 9, pp.1958-1972.
      39. Огнерубов Н. А., Иванов А. А., Чанг В. Л. и соавт. Колоректальный рак в Тамбовской области: некоторые аспекты эпидемиологии. Вестник Тамбовского университета. Серия: Естественные и техническиенауки, 2015, т. 20, № 6, с. 1679-1684.
      40. Schernhammer E. C., Leitzmann M.F, Michaud D. S. et al. Cholecystectomy and the risk for developing colorectal cancer and distal colorectal adenomas. British journal of cancer, 2003, vol. 88, pp. 79-83.
      41. Панышин Г. А., Рыбаков Ю. Н., Зотов В. К. и соавт. К вопросу о местных лучевых повреждениях прямой кишки у больных раком шейки матки. Вестник Российского научного центра рентгенорадиологии Минздрава России, 2010, т. 2, № 10, c. 2-10.
      42. Combs G. F., Lu J., Hatfield D. et al. Selenium as a cancer preventive agent // Selenium: Its molecular biology and role in human health. New York: Springer, 2006, pp. 249-264.
      43. Rayman M. P. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc. Nutr. Soc, 2005, vol. 64, pp. 527-542.
      44. Schrauzer G. N. Anticarcinogenic effects of selenium. Cell. Mol. Life Sci, 2000, vol. 57, pp. 1864-1874.
      45. Кляритская И. Л., Иськова И. А. Роль алкоголя в возникновении рака желудочно- кишечного тракта. Крымский терапевтический журнал, 2007, т.2, № 2, c. 18-23.
      46. Hagland R. H., Soreide K. Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways. Cancer Letters, 2015., vol. 356, № 2, pp. 273-280.
      47. Осадчук М. А., Балашов Д. В., Осадчук М. М. Запоры в поликлинической практике. Поликлиника, 2015, № 1, c. 90-94.
      48. Попенко А. С. Биоинформационное исследование таксономического состава миктобиоты кишечника человека. 2014. URL: http://www.ibmc.msk.ru/content/thesisDocs/PopenkoAS_thesis.pdf (дата обращения 05.01.2016)
      49. Antonic V., Stojadinovic A., Kent E. et al. Significance of Infectious Agents in Colorectal Cancer Development. Journal of Cancer, 2013, no.3, pp.241-244.
      50. Ron E., Gridley G., Hrubec Z., et al. Acromegaly and gastrointestinal cancer. Cancer, 1991, no. 68, pp. 1673-1677.
      51. Barzilay J., Heatley G.J, Gushing GW. Benign and malignant tumors in patients with acromegaly. ArchInternMed, 1991, no. 151, pp. 1629-1632.
      52. Ma J. Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3. Jnl of National Cancer Institute, 2013, vol. 91, pp. 620-625.
      53. Swerdlow A. J. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. The lancet, 2002, vol. 360, № 9329, pp. 273-277.
      54. Овсянников В.И., Шемеровский К. А. Хронофизиологический подход к профилактике колоректального рака. Научно-практический журнал Вопросы онкологии, 2013, № 3, c. 629-630.
      55. Cross A. J., Leitzmann A. F., Gail M. N. et al. Prospective study of red and processed meat intake in relation to cancer risk. PLOS, 2007, URL: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0040325 (дата обращения: 11.11.2016).
      56. McTiernan A. Cancer Prevention and Management Through Exercise and Weight Control. BocaRaton: Taylor&FrancisGroup, LLC, 2006, no. 23, pp. 13-14.
      57. Reddy B. S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res, 1987, no. 47, pp. 5340-5346.
      58. Moorghen M., Ince P., Finney K.J, et al. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol, 1988, no.156, pp. 341-347.
      59. Chan A. T., Giovannucci E. L., Meyerhardt J. A., et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA, 2005, no. 294, pp. 914-923.
      60. Baron J. A., Cole B. F., Sandier R. S., et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med, 2003, no. 348, pp. 891-899.
      61. Sandier R. S., Halabi S., Baron J. A., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. NEnglJMed, 2003, no. 348, pp. 883-890.
      62. Burn J., Gerdes A., Macrae F., et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. The Lancet, 2012, № 9809, pp. 2081-2087.
      63. Hackethal V. Long-term Aspirin Tied to Small Drop in Overall Cancer Risk. Medscape Medical News, 2016, no. 14, pp. 23-25.
      64. Chung Y.M, Bae Y.S, Lee S. Y. Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. Free RadicBiol Med, 2003, vol. 34, pp. 434-442.
      65. Pathi S. Aspirin Inhibits Colon Cancer Cell and Tumor Growth and Downregulates Specificity Protein (Sp) Transcription Factors. PLOS. URL: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0048208 (дата обраащения: 07.01.2017)
      66. Paterson J., Baxter G. Is there a role for dietary salicylates in health?. ProcNutr Soc, 2006, vol. 65, pp. 93-96.
      67. Davies R., Hibbitt S., Hood K., et al. Natural Salicylates and Cancer. Held in the All Nations Centre, 2013. URL: http://www.wspcr.ac.uk/resources/SUMMARY%20OF%20NATURAL%20SALICYLATES%20MEETING.pdf (дата обращения 07.01.2017)
      68. Никитина Н. В., Белоусова Е. А. Язвенный колит и рак толстой кишки: формирование групп риска, скрининг и профилактика. Фарматека для практикующих врачей, 2004, № 13.
      69. Nelson R., Oils M. Lower Risk for Colorectal Cancer Subtype. J Natl Cancer Inst, 2015.
      70. Fujiki H. Primary cancer prevention by green tea, and tertiary cancer prevention by the combination of green tea catechins and anticancer compounds, 2015 www.europepmc.org/articles/pmc4384709 + /link.springer.com/article/10.1007/s00432-014-1899-5
      71. Schmit S. L., Rennert H. S., Rennert G., Gruber S. B. Coffee Consumption and the Risk of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev, 2016, no. 25, pp. 634-639.
      72. Spaan M. Colorectal cancer risk after ovarian stimulation for in vitro fertilization. ASRM Abstracts, 2014, vol. 102, № 3, pp. 50-51.
      73. Manser C. N., Bauerfeind P. Impact of socioeconomic status on incidence, mortality, and survival of colorectal cancer patients: a systematic review. Gastrointestinal endoscopy, 2014, vol. 80, № 1, pp. 42-69.
      74. Jacobs E. J., Rodriguez C., Brady K. A., et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst, 2006, no. 98, pp. 69-72.
      75. Poynter J. N., Gruber S. B., Higgins P. D., et al. Statins and the risk of colorectal cancer. N Engl J Med, 2005, no. 352, pp. 2184-2192.
      76. Setoguchi S. Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly. Circulation, 2007, vol. 115, № 1.
      77. Jenny N., Poynter M. P., Stephenet B. et al. Statins and the Risk of Colorectal Cancer. The new England journal of medicine, 2005, vol. 352, pp. 2184-2192.
      78. Bonovas S., Fillioussi K., Flordellis C., et al. Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 18 Studies Involving More Than 1.5 Million Patients. Journal of Clinical Oncology, 2007, vol. 25, pp. 3462-3468.
      79. Wolf J. M., Lashner B. A., Rybicki L. A. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Alimentary pharmacology and therapeutics, 2005, vol. 22, № 9, pp. 783-788.
      80. Alberts D. S. Phase III Trial of Ursodeoxycholic Acid To Prevent Colorectal Adenoma Recurrence. Jnl of National Cancer Institute, 2005, vol. 97, № 11, pp. 846-853.
      81. Eaton E. J. High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis. The American Journal of Gastroenterology, 2011, vol. 106, pp. 1638-1645.
      82. Noto H., Goto A., Tsujimoto T., Noda M. Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis. PLoS ONE, 2012, no.3, pp. 20-25.
     


    Full text is published :
    Prudnikova Ya.I., Kruchinina M.V., Svetlova I.O., Kurilovich S.A. et al. COLORECTAL CANCER: FACTORS OF RISK AND PROTECTION. Experimental and Clinical Gastroenterology Journal. 2017;145(09):96-105
    Read & Download full text

    1. Research Institute of Internal and Preventive Medicine - Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences (Novosibirsk, Russian Federation)
    2. Federal Budgetary Research Institution “State Research Center of Virology and Biotechnology «Vector»”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being (Novosibirsk, Russian Federation)

    Keywords:fatty liver disease,alcoholic,nonalcoholic genesis,erythrocytes,electrical,viscoelastic parameters,dynamics of withdrawal

    Abstract:The purpose of the work was to study the electrical and viscoelastic parameters of erythrocytes in patients with fatty liver disease of alcoholic and non-alcoholic genesis in the dynamics of withdrawal symptoms and weight loss. Materials and methods. The electrical and viscoelastic parameters of erythrocytes have been studied by the method of dielectrophoresis in 22 men (56,4 ± 2,2 years) with nonalcoholic and 24 with fatty liver of alcoholic genesis (57,2 ± 2,7 years) in the dynamics of withdrawal syndrome and weight loss (within 2,5-3 months). Results. In the dynamics of the abstinence syndrome in patients with fatty liver disease of alcoholic genesis a significant decrease in the diameter of erythrocytes, summarized viscosity, rigidity, electrical conductivity, indexes of destruction, aggregation and increase of the amplitude of cell deformation, polarizability, magnitude of the dipole moment, cell capacitance were determined; the crossover frequency was shifted to the low-frequency range (p<0,001-0,05). The revealed changes correlated with a decrease of the transaminase activity, de Ritis coefficient, GGTP, the average corpuscular volume of erythrocytes. In patients with fatty liver disease of non-alcoholic genesis at the background of weight loss (5-7 % of the initial body weight) there was no significant change in erythrocyte parameters. Conclusion. Differences in the dynamics of erythrocyte parameters at the background of abstinence and weight loss in patients with fatty liver disease can be used for differential diagnosis of alcoholic and non-alcoholic genesis of the disease.

      1. Метаболический синдром / Под ред. чл.- корр. РАМН Г. Е. Ройтберга. - М.: Медпресс-информ, 2007. - 224 с.
      2. Bellentani S, Scaglioni F., Marino M., Bedogni G. Epidemiology of non-alcoholic fatty liver disease // Dig Dis., 2010, Vol. 28, No. 1, P. 155-61.
      3. Курилович С. А., Решетников О. В. Эпидемиология заболеваний органов пищеварения в Западной Сибири, Новосибирск, 2000. - 165 с.
      4. Махов В. М. Алкогольная болезнь печени и неалкогольная жировая болезнь печени - общность и различия // Лечащий врач, 2012, Т. 7, С. 22-28.
      5. Fan J. G., Saibara T., Chitturi S., B. I. Kim B. I., Sung J. J., Chutaputti A. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? // J. Gastroenterol. Hepatol., 2007, Vol. 22, No. 6., P. 794-800.
      6. Драпкина О. М., Смирин В. И., Ивашкин В. Т. Патогенез, лечение и эпидемиология НАЖБП - что нового? Эпидемиология НАЖБП в России // РМЖ, 2011, Т. 28, С. 1717-1721.
      7. Morgan M. Y. The prognosis and outcome of alcoholic liver disease. // Alcohol. Alcohol., 1994, Vol. 2, Suppl., P. 335-43.
      8. Rich H. G. Resolution of focal fatty infiltration of the liver // South Med. J., 1996, Vol. 89, No. 10, P. 1024-27.
      9. Хомерики С. Г., Хомерики Н. М. Алкогольная болезнь печени: механизмы развития, морфологические проявления, дифференциальная диагностика и патогенетические подходы к терапии // Consilium medicum. Гастроэнтерология, 2012, Т. 1, С. 27-34.
      10. Новицкий В. В., Рязанцева Н. В., Степовая Е. А. Физиология и патофизиология эритроцита. Томск: Изд-во Том. Ун-та, 2004. - 202 c.
      11. Шиффман Ф. Дж. Патофизиология крови / Пер с англ. Жибурта Е. Б., Токарева Ю. Н. - М.-СПб.: «Издательство БИНОМ» - «Невский диалог», 2000. - 448 с.
      12. Генералов В. М., Кручинина М. В., Дурыманов, А.Г., Медведев А. А., Сафатов А. С., Сергеев А. Н., Буряк Г. А., Курилович С. А., Громов А. А. Диэлектрофорез в диагностике инфекционных и неинфекционных заболеваний. - Новосибирск: Изд-во «ЦЭРИС», 2011. - 172 с.
      13. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр // Кардиоваскулярная терапия и профилактика, 2009, № 6., С. 1-29.
      14. Сторожок С. А., Панченко Л. Ф.,. Филиппович Ю.Д, Глушков В. С. Изменения физико-химических свойств биологических мембран при развитии толерантности к этанолу // Вопросы медицинской химии, 2001, № 2, С. 42-51.
      15. Laposata M. Fatty acid ethyl esters: nonoxidative ethanol metabolites with emerging biological and clinical significance // Lipids. 1999, Vol. 34, P. S 281-S 285.
      16. Gurtovenko A. A., Anwar J. Interaction of ethanol with biological membranes: The formation of non-bilayer structures within the membrane interior and their significance // J. Phys. Chem. B., 2009, Vol. 113, P. 1983-1992.
      17. Varga A., Alling C. Formation of phosphatidylethanol in vitro in red blood cells from healthy volunteers and chronic alcoholics // J. Lab. Clin. Med., 2002, Vol. 140, No. 2, P. 79-83.
      18. Tyulina, O. V., Prokopieva V.D, Dodd R. D., Hawkins J. R., Clay S. W., Wilson D. O., Boldyrev A. A., Johnson P. In vitro effects of ethanol, acetaldehyde and fatty acid ethyl esters on human erythrocytes // Alcohol. Alcohol., 2002, Vol. 37, No. 2, P. 179-86.
      19. Chi L. M., Wu W. G. Mechanism of hemolysis of red blood cell mediated by ethanol // Biochim. Biophys. Acta, 1991, Vol. 1062, P. 46-50.
      20. Litvinov R. I., Weisel J. W. Role of red blood cells in haemostasis and thrombosis // ISBT Sci Ser., 2017, Vol. 12, No. 1, P. 176-183.
      21. Rabai M., Detterich R. J., Wenby A. B., K. Toth K., Meiselman H. J. Effects of ethanol on red blood cell rheological behavior // Clin. Hemorheol. Microcirc, 2014, Vol. 56, No. 2, P. 87-99.
      22. Peterson K. Biomarkers for Alcohol Use and Abuse // Alcohol Research & Health, 2004/2005, Vol. 28, No. 1, P. 30-37.
      23. Elizondo A., Aray J., Rodrigo R., Signorini C., Sgherri C., Comporti M., Poniachik J., Videla L. A. Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease // Biol. Res. - 2008. - Vol. 41, No. 1. - P. 59-68.
      24. Oshino N., Oshino R., Chance B. The characteristics of the ‘peroxidatic’ reaction of catalase in ethanol oxidation // Biochem. J., 1973, Vol. 131, P. 555-567.
      25. Zorzano A., Ruiz del Arbol L., Herrera E. Effect of liver disorders on ethanol elimination and alcohol and aldehyde dehydrogenase activities in liver and erythrocytes // Clin. Sci. - 1989. - Vol. 76. - P. 51-57.
      26. Hamby-Mason R., Chen J. J., Schenker S., Perez A., Henderson G. I. Catalase mediates acetaldehyde formation from ethanol in fetal and neonatal rat brain // Alcohol. Clin. Exp. Res., 1997, Vol. 21, P. 1063-1072.
      27. Tephly T. R., Mannering G. J., Parks R. E. Studies on the mechanism of inhibition of liver and erythrocyte catalase activity by 3-amino-1,2,4-triazole (AT) // J. Pharmacol. Exp. Ther., 1961, Vol. 133, P. 77-82.
      28. Meier-Tackmann D., Leonhardt R. A., Agarwal, D.P., Goedde H. W. Effect of acute ethanol drinking on alcohol metabolism in subjects with different ADH and ALDH genotypes // Alcohol., 1990, Vol. 7, P. 413-418.
     


    Full text is published :
    Kruchinina M.V., Parulikova M.V., Kurilovich S.A., Gromov A.A. et al. CHANGE OF ERYTHROCYTE, S PARAMETERS IN PATIENTS WITH FAT LIVER DISEASE OF ALCOHOL AND NON-ALCOHOL GENESIS IN THE DYNAMICS OF ABSTENTINE SYNDROME AND DECREASE OF BODY MASS. Experimental and Clinical Gastroenterology Journal. 2017;145(09):106-115
    Read & Download full text